logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
20/12/2025
Google: Files lawsuit against Serpapi company, requests court to prohibit its web crawlers and malicious data scraping activities.
Latest
2 m ago
Fed Governor Milan: If there is a vacancy at the Federal Reserve, Trump may decide to nominate me for the position.
2 m ago
The Brazilian Congress approved the budget for the year 2026.
5 m ago
President Trump and nine major pharmaceutical companies announced on Friday that they have reached an agreement to significantly reduce the prices of their drugs in government healthcare programs and for patients paying in cash. Pfizer, Gilead Sciences, Merck, and Roche's American subsidiary Genentech have all reached agreements. Novartis, Amgen, Bristol-Myers Squibb, Sanofi, and GlaxoSmithKline have also joined. Under the agreement, pharmaceutical companies will lower the prices of most drugs sold to low-income patients in healthcare programs and promise "significant savings" on widely used medications. Trump has been pressuring pharmaceutical companies to lower drug prices to the levels paid by patients in other countries. In July, Trump wrote a letter to the leaders of 17 major pharmaceutical companies urging them to provide "most favored nation" prices to healthcare programs and ensure that new drugs are not priced higher in the U.S. than in other wealthy countries. Five companies have already reached agreements with the government to control drug prices, while the remaining three companies that have not yet announced agreements are Regeneron, Johnson & Johnson, and AbbVie.
5 m ago
Merck: Reaches agreement with the US Department of Commerce to delay tariffs for three years. Merck aims to expand drug access channels and lower drug costs for American people, with Januvia, Janumet, and Janumet XR being supplied to eligible US patients at a cash price approximately 30% off the current list price. The company also pledges to invest over $70 billion in the United States.
7 m ago
Federal Reserve Governor Mester: The labor market is developing in a direction that we should stop.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.